What is AbbVie EV-to-FCF?
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, AbbVie's Enterprise Value is $329,271 Mil. AbbVie's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was $21,891 Mil. Therefore, AbbVie's EV-to-FCF for today is 15.04.
The historical rank and industry rank for AbbVie's EV-to-FCF or its related term are showing as below:
ABBV' s EV-to-FCF Range Over the Past 10 Years
Min: 9.95 Med: 15.8 Max: 38.43
Current: 15.04
During the past 13 years, the highest EV-to-FCF of AbbVie was 38.43. The lowest was 9.95. And the median was 15.80.
ABBV's EV-to-FCF is ranked better than
65.85% of 530 companies
in the Drug Manufacturers industry
Industry Median: 22.78 vs ABBV: 15.04
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-05-30), AbbVie's stock price is $156.31. AbbVie's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $3.370. Therefore, AbbVie's PE Ratio for today is 46.38.
AbbVie EV-to-FCF Historical Data
The historical data trend for AbbVie's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
AbbVie EV-to-FCF Chart
AbbVie Annual Data | ||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||||||
EV-to-FCF | Get a 7-Day Free Trial | 12.35 | 15.89 | 13.93 | 14.02 | 14.52 |
AbbVie Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
EV-to-FCF | Get a 7-Day Free Trial | 14.31 | 11.70 | 12.56 | 14.52 | 17.24 |
Competitive Comparison of AbbVie's EV-to-FCF
For the Drug Manufacturers - General subindustry, AbbVie's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AbbVie's EV-to-FCF Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AbbVie's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where AbbVie's EV-to-FCF falls into.
AbbVie EV-to-FCF Calculation
AbbVie's EV-to-FCF for today is calculated as:
EV-to-FCF | = | Enterprise Value (Today) | / | Free Cash Flow (TTM) |
= | 329270.674 | / | 21891 | |
= | 15.04 |
AbbVie's current Enterprise Value is $329,271 Mil.
AbbVie's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $21,891 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AbbVie(NYSE:ABBV) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
AbbVie's PE Ratio for today is calculated as:
PE Ratio | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 156.31 | / | 3.370 | |
= | 46.38 |
AbbVie's share price for today is $156.31.
AbbVie's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.370.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
AbbVie EV-to-FCF Related Terms
Thank you for viewing the detailed overview of AbbVie's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
AbbVie (AbbVie) Business Description
Industry
GURUFOCUS.COM »STOCK LIST »Healthcare » Drug Manufacturers » AbbVie Inc (NYSE:ABBV) » Definitions » EV-to-FCF
Comparable Companies
MRK PFE JNJ AMGN BMY GILD BIIB OGN SCLX AMRN LLY XSWX:ROG LSE:AZN XSWX:NOVN XPAR:SAN LSE:GSK TSE:4568 TSE:4519 XTER:BAYN SHSE:600276
Traded in Other Exchanges
Address
1 North Waukegan Road, North Chicago, IL, USA, 60064-6400
Website
AbbVie is a pharmaceutical firm with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Executives
Nicholas Donoghoe | officer: SVP, Enterprise Innovation | 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064 |
Susan E Quaggin | director | 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064 |
Jennifer L. Davis | director | 1 PROCTER & GAMBLE PLAZA, CINCINNATI OH 45202 |
Richard A Gonzalez | officer: Chairman of the Board and CEO | 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064 |
Elaine K. Sorg | officer: Sr. V.P., U.S. Commercial Ops. | 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064 |
Perry C Siatis | officer: EVP, GC and Secretary | 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064 |
Jeffrey Ryan Stewart | officer: SVP, US Commercial Operations | 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064 |
Kevin K Buckbee | officer: SVP, Controller | 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064 |
Scott T Reents | officer: SVP, Chief Financial Officer | 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064 |
Azita Saleki-gerhardt | officer: SVP, Operations | 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064 |
Carrie C Strom | officer: SVP & Pres Global Allerg Aesth | 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064 |
Roxanne S Austin | director | 200 N SEPULVEDA BLVD, PO BOX 956 MS ES/001/A102, EL SEGUNDO CA 90245 |
Timothy J. Richmond | officer: EVP, Chief HR Officer | 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064 |
Michael Severino | officer: EVP, R&D and CSO | 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064 |
Henry O Gosebruch | officer: Chief Strategy Officer | 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064-6092 |
AbbVie (AbbVie) Headlines
From GuruFocus
Abbvie Inc at Sanford C Bernstein Strategic Decisions Conference Transcript
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-22-2024
Abbvie Inc at Morgan Stanley Global Healthcare Conference Transcript
By GuruFocus Research • 01-22-2024
Abbvie Inc at Piper Sandler Healthcare Conference (Virtual) Transcript
By GuruFocus Research • 01-22-2024
Abbvie Inc at Cowen Health Care Conference (Virtual) Transcript
By GuruFocus Research • 01-22-2024
Abbvie Inc at Evercore ISI HealthCONx Virtual Conference Transcript
By GuruFocus Research • 01-22-2024
Abbvie Inc at Evercore ISI HealthCONx Conference (Virtual) Transcript
By GuruFocus Research • 01-22-2024
Abbvie Inc at Barclays Global Healthcare Conference Transcript
By GuruFocus Research • 01-22-2024
Abbvie Inc at Goldman Sachs Healthcare Conference Transcript
By GuruFocus Research • 01-22-2024
Abbvie Inc at JPMorgan Healthcare Conference Transcript
By GuruFocus Research • 01-22-2024